- Biohaven (BHVN, Financial) showcases promising early clinical results for its Trop2 ADC, BHV-1510, with tumor reduction observed in all treated patients.
- First patient dosed with the novel FGFR3-directed ADC, BHV-1530, highlighting potential in FGFR3-driven cancers.
- Biohaven advances strategic collaborations with Merus and GeneQuantum to enhance its ADC pipeline.
Biohaven Ltd. (BHVN), a clinical-stage biopharmaceutical company, unveiled exciting updates from its oncology programs at the 2025 R&D Day. The company presented preliminary clinical data for BHV-1510, a Trop2-directed antibody drug conjugate (ADC), which demonstrated encouraging clinical activity both as a standalone therapy and in combination with Regeneron's cemiplimab. Remarkably, all six patients treated with the BHV-1510/cemiplimab combination therapy showed tumor reduction, including confirmed partial responses. Notably, the safety profile was favorable, with manageable toxicity and no cases of interstitial lung disease.
Furthermore, Biohaven announced the dosing of the first patient with BHV-1530, its novel FGFR3-directed ADC, marking a potential first-in-class treatment aimed at FGFR3-driven cancers such as urothelial cancers. This development holds promise for targeting cancer types driven by FGFR3 alterations or overexpression.
Biohaven is also expanding its innovative antibody-drug conjugate (ADC) platform through collaborations with Merus and GeneQuantum. These partnerships aim to leverage Biohaven's proprietary TopoIx payload technology, which has shown promise in preclinical studies for inducing immunogenic cell death and enhancing synergy with PD-1/PD-L1 inhibitors, potentially leading to more durable responses in cancer therapy.
Biohaven's advancements in the ADC landscape are underpinned by the proprietary TopoIx technology, which could pave the way for multiple clinical candidates with enhanced potency and selectivity. This positions Biohaven as a notable player in the field, with its ongoing efforts to address a broad spectrum of challenging tumor types through its innovative ADC pipeline.
